These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 9607328)
1. Caveolin-3 is not an integral component of the dystrophin glycoprotein complex. Crosbie RH; Yamada H; Venzke DP; Lisanti MP; Campbell KP FEBS Lett; 1998 May; 427(2):279-82. PubMed ID: 9607328 [TBL] [Abstract][Full Text] [Related]
2. Expression of caveolin-3 in skeletal, cardiac, and smooth muscle cells. Caveolin-3 is a component of the sarcolemma and co-fractionates with dystrophin and dystrophin-associated glycoproteins. Song KS; Scherer PE; Tang Z; Okamoto T; Li S; Chafel M; Chu C; Kohtz DS; Lisanti MP J Biol Chem; 1996 Jun; 271(25):15160-5. PubMed ID: 8663016 [TBL] [Abstract][Full Text] [Related]
3. Dystroglycan and muscular dystrophies related to the dystrophin-glycoprotein complex. Sciandra F; Bozzi M; Bianchi M; Pavoni E; Giardina B; Brancaccio A Ann Ist Super Sanita; 2003; 39(2):173-81. PubMed ID: 14587215 [TBL] [Abstract][Full Text] [Related]
4. Dystroglycan is not required for localization of dystrophin, syntrophin, and neuronal nitric-oxide synthase at the sarcolemma but regulates integrin alpha 7B expression and caveolin-3 distribution. Côté PD; Moukhles H; Carbonetto S J Biol Chem; 2002 Feb; 277(7):4672-9. PubMed ID: 11741881 [TBL] [Abstract][Full Text] [Related]
5. The dystrophin glycoprotein complex: signaling strength and integrity for the sarcolemma. Lapidos KA; Kakkar R; McNally EM Circ Res; 2004 Apr; 94(8):1023-31. PubMed ID: 15117830 [TBL] [Abstract][Full Text] [Related]
6. Dystrophin-glycoprotein complex and laminin colocalize to the sarcolemma and transverse tubules of cardiac muscle. Klietsch R; Ervasti JM; Arnold W; Campbell KP; Jorgensen AO Circ Res; 1993 Feb; 72(2):349-60. PubMed ID: 8418988 [TBL] [Abstract][Full Text] [Related]
7. Interactions between dystrophin and the sarcolemma membrane. Chamberlain JS; Corrado K; Rafael JA; Cox GA; Hauser M; Lumeng C Soc Gen Physiol Ser; 1997; 52():19-29. PubMed ID: 9210217 [TBL] [Abstract][Full Text] [Related]
8. Caveolin-3 and sarcoglycans in the vacuolar myopathies and centronuclear myopathy. Inose M; Higuchi I; Nakagawa M; Kashio N; Osame M Muscle Nerve; 1999 Aug; 22(8):1080-6. PubMed ID: 10417791 [TBL] [Abstract][Full Text] [Related]
9. Disrupted mechanical stability of the dystrophin-glycoprotein complex causes severe muscular dystrophy in sarcospan transgenic mice. Peter AK; Miller G; Crosbie RH J Cell Sci; 2007 Mar; 120(Pt 6):996-1008. PubMed ID: 17311848 [TBL] [Abstract][Full Text] [Related]
10. Dystrophin-glycoprotein complex: its role in the molecular pathogenesis of muscular dystrophies. Matsumura K; Campbell KP Muscle Nerve; 1994 Jan; 17(1):2-15. PubMed ID: 8264699 [TBL] [Abstract][Full Text] [Related]
11. Utrophin and dystrophin-associated glycoproteins in normal and dystrophin deficient cardiac muscle. Rivier F; Robert A; Royuela M; Hugon G; Bonet-Kerrache A; Mornet D J Muscle Res Cell Motil; 1999 Apr; 20(3):305-14. PubMed ID: 10471993 [TBL] [Abstract][Full Text] [Related]
12. Differential distribution of dystrophin and beta-spectrin at the sarcolemma of fast twitch skeletal muscle fibers. Williams MW; Bloch RJ J Muscle Res Cell Motil; 1999 May; 20(4):383-93. PubMed ID: 10531619 [TBL] [Abstract][Full Text] [Related]
13. Microdystrophin gene therapy of cardiomyopathy restores dystrophin-glycoprotein complex and improves sarcolemma integrity in the mdx mouse heart. Yue Y; Li Z; Harper SQ; Davisson RL; Chamberlain JS; Duan D Circulation; 2003 Sep; 108(13):1626-32. PubMed ID: 12952841 [TBL] [Abstract][Full Text] [Related]
14. A role for the dystrophin-glycoprotein complex as a transmembrane linker between laminin and actin. Ervasti JM; Campbell KP J Cell Biol; 1993 Aug; 122(4):809-23. PubMed ID: 8349731 [TBL] [Abstract][Full Text] [Related]
15. Dystrophin-associated glycoprotein and dystrophin co-localisation at sarcolemma in Fukuyama congenital muscular dystrophy. Arahata K; Hayashi YK; Mizuno Y; Yoshida M; Ozawa M Lancet; 1993 Sep; 342(8871):623-4. PubMed ID: 8102757 [No Abstract] [Full Text] [Related]
16. Altered distribution of beta-dystroglycan in sarcolemma of human dystrophic muscles: an immunohistochemical study. Jimi T; Wakayama Y; Takeda A; Kobayashi T; Kumagai T; Suzuki Y; Hasegawa O; Yamashita S; Shibuya S; Kuroiwa Y Muscle Nerve; 1995 Aug; 18(8):910-3. PubMed ID: 7630355 [No Abstract] [Full Text] [Related]
17. Caveolin-3 and nitric oxide synthase I in healthy and diseased skeletal muscle. Gossrau R Acta Histochem; 1998 Feb; 100(1):99-112. PubMed ID: 9542584 [TBL] [Abstract][Full Text] [Related]
18. Caveolin-3 directly interacts with the C-terminal tail of beta -dystroglycan. Identification of a central WW-like domain within caveolin family members. Sotgia F; Lee JK; Das K; Bedford M; Petrucci TC; Macioce P; Sargiacomo M; Bricarelli FD; Minetti C; Sudol M; Lisanti MP J Biol Chem; 2000 Dec; 275(48):38048-58. PubMed ID: 10988290 [TBL] [Abstract][Full Text] [Related]
19. Muscular dystrophies involving the dystrophin-glycoprotein complex: an overview of current mouse models. Durbeej M; Campbell KP Curr Opin Genet Dev; 2002 Jun; 12(3):349-61. PubMed ID: 12076680 [TBL] [Abstract][Full Text] [Related]
20. Changes in the distribution and density of caveolin 3 molecules at the plasma membrane of mdx mouse skeletal muscles: a fracture-label electron microscopic study. Shibuya S; Wakayama Y; Inoue M; Oniki H; Kominami E Neurosci Lett; 2002 Jun; 325(3):171-4. PubMed ID: 12044648 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]